The company was founded in 1992 as Drug Royalty Corporation by Alan Grieve, the company's first president and CEO. In its first fiscal year of operation, it went public on the Toronto Stock Exchange and purchased a royalty interest in the pioneering British biotech firm, Cambridge Antibody Technology Limited.
